Elanco Logo

Baytril® 100 (Enrofloxacin)

Baytil logo

Baytril® 100 (Enrofloxacin)

For the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica, and Mycoplasma hyopneumoniae (M. hyo). For the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli (E. coli) has been diagnosed.

The Reliable SRD Solution

  • Quick.
  • Reliable.
  • Effective.

Respiratory disease occurrence and severity is affected by factors such as weaning, handling, temperature and ventilation.1 Baytril® 100 helps manage SRD and E. coli challenges that can be exacerbated by environmental stressors allowing producers to optimize full value from start to finish.

Fights against 6 SRD pathogens and E. coli


Effective bactericidal mode of action


1 dose treatment


A Full Value Solution

  • Baytril is highly bioavailable, reaching the lungs quickly for effective treatment. Baytril’s active ingredient, enrofloxacin, binds to DNA gyrase in Gram negative bacteria and topoisomerase IV in Gram positive bacteria, making it bactericidal and concentration-dependent which differentiates it from cephalosporins and macrolides.
  • Early SRD intervention is critical to assure good nursery pig health and to support the subsequent profitability in the finishing phase.

Baytil logo

Baytril Product Label

Read the full label for important use and safety information

Download Label

Get Full Value from start to finish

Our portfolio offers solutions that manage disease challenges and mitigate mortality to optimize health.

Swine Intestinal Integrity

Intestinal Integrity

Elanco offers feed, water-soluble and injectable intestinal integrity solutions.

See the Portfolio
Swine Respiratory Health

Respiratory Health

Managing both enteric and respiratory health challenges are critical to your herd's success.

See the Portfolio

The label contains complete use information, including cautions and warnings. Always read, follow and understand the label and use directions.

INDICATIONS:

  • For the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica, and Mycoplasma hyopneumoniae.
  • For the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli has been diagnosed.

DOSAGE AND ADMINISTRATION:

  • Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Administered dose volume should not exceed 5 mL per injection site.
  • For the control of colibacillosis, administration should be initiated within the first 60 days post-weaning when clinical signs are present in at least 2% of the animals in the group. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

IMPORTANT SAFETY INFORMATION:

CAUTION:  Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (U.S.A.) law prohibits the extra-label use of this drug in food-producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.

  • Not for use in humans. Keep out of reach of children.
  • Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes.
  • In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures.
  • Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.